Skip to main content Accessibility help
×
Home

Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient

  • Irene Worthington (a1), Tamara Pringsheim (a2), Marek J. Gawel (a1) (a3) (a4), Jonathan Gladstone (a1) (a5), Paul Cooper (a6), Esma Dilli (a7), Michel Aube (a8), Elizabeth Leroux (a9), Werner J. Becker (a2) and on behalf of the Canadian Headache Society Acute Migraine Treatment Guideline Development Group...

Abstract:

Background:

In our targeted review (Section 2), 12 acute medications received a strong recommendation for use in acute migraine therapy while four received a weak recommendation for use. Strong recommendations were made to avoid use of two other medications, except for exceptional circumstances. Two anti-emetics received strong recommendations for use as needed.

Objective:

To organize the available acute migraine medications into acute migraine treatment strategies in order to assist the practitioner in choosing a specific medication(s) for an individual patient.

Methods:

Acute migraine treatment strategies were developed based on the targeted literature review used for the development of this guideline (Section 2), and a general literature review. Expert consensus groups were used to refine and validate these strategies.

Results:

Based on evidence for drug efficacy, drug side effects, migraine severity, and coexistent medical disorders, our analysis resulted in the formulation of eight general acute migraine treatment strategies. These could be grouped into four categories: 1) two mild-moderate attack strategies, 2) two moderate-severe attack or NSAID failure strategies, 3) three refractory migraine strategies, and 4) a vasoconstrictor unresponsive-contraindicated strategy. In addition, strategies were developed for menstrual migraine, migraine during pregnancy, and migraine during lactation. The eight general treatment strategies were coordinated with a “combined acute medication approach” to therapy which used features of both the “stratified” and the “step care across attacks” approaches to acute migraine management.

Conclusions:

The available medications for acute migraine treatment can be organized into a series of strategies based on patient clinical features. These strategies may help practitioners make appropriate acute medication choices for patients with migraine.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient
      Available formats
      ×

Copyright

Corresponding author

Division of Neurology, 12th Floor, Foothills Hospital, 1403 29th St NW, Calgary, Alberta, T2N 2T9, Canada

References

Hide All
1.Lipton, RB, Stewart, WF, Stone, AM, Lainez, MJ, Sawyer, JP, Disability in Strategies of Care Study, group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial.[see comment]. JAMA. 2000;284:2599605.
2.Lipton, RB, Baggish, JS, Stewart, WF, Codispoti, JR, Fu, M.Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med. 2000;160:348692.
3.Prior, MJ, Codispoti, JR, Fu, M.A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache. Headache. 2010;50:81933.
4.Hamalainen, ML, Hoppu, K, Valkeila, E, Santavuori, P.Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology. 1997;48:1037.
5.Larsen, BH, Christiansen, LV, Andersen, B, Olesen, J.Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine. Acta Neurol Scand. 1990;81:4647.
6.Ottani, A, Leone, S, Sandrini, M, Ferrari, A, Bertolini, A.The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol. 2006;531:2801.
7.Cooke, LJ, Becker, WJ.Migraine prevalence, treatment and impact: the canadian women and migraine study. Can J neurol Sci. 2010; 37:5807.
8.Suthisisang, C, Poolsup, N, Kittikulsuth, W, Pudchakan, P, Wiwatpanich, P.Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother. 2007;41:178291.
9.Rabbie, R, Derry, S, Moore, RA, McQuay, HJ.Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;008039.
10.Diener, HC, Bussone, G, de Liano, H, et al.Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004;24:94754.
11.Suthisisang, C, Poolsup, N, Suksomboon, N, Lertpipopmetha, V, Tepwitukgid, B.Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache. 2010;50:80818.
12.Derry, S, Rabbie, R, Moore, RA.Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2012;2:008783.
13.Diener, HC, Montagna, P, Gacs, G, et al.Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26:53747.
14.Kirthi, V, Derry, S, Moore, RA, McQuay HJ. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;4:008041.
15.Lampl, C, Voelker, M, Diener, HC.Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol. 2007;254:70512.
16.Shields, KG, Goadsby, PJ.Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol Dis. 2006;23:491501.
17.Loder, E.Triptan therapy in migraine. N Engl J Med. 2010;363: 6370.
18.Goldstein, DJ, Roon, KI, Offen, WW, et al.Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001;358:12304.
19.Ferrari, MD, Goadsby, PJ, Roon, KI, Lipton, RB.Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.[see comment][erratum appears in Cephalalgia. 2003 Feb;23(1):71.]. Cephalalgia. 2002;22:63358.
20.Cady, RK, Freitag, FG, Mathew, NT, et al.Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention. Headache. 2009;49:35063.
21.Bigal, ME, Serrano, D, Buse, D, Scher, A, Stewart, WF, Lipton, RB.Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:115768.
22.Anonymous Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med. 1991;325:31621.
23.Gawel, MJ, Worthington, I, Maggisano, A.A systematic review of the use of triptans in acute migraine.[see comment]. [Review] [74 refs]. Can J Neurol Sci. 2001;28:3041.
24.Tfelt-Hansen, P, De Vries, P, Saxena, PRTriptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60:125987.
25.Gladstone, JP, Gawel, M.Newer formulations of the triptans: advances in migraine management. [Review] [116 refs]. Drugs. 2003;63:2285305.
26.Rapoport, AM, Tepper, SJ, Bigal, ME, Sheftell, FD.The triptan formulations : how to match patients and products. [Review] [75 refs]. CNS Drugs. 2003;17:43147.
27.Dodick, DW, Lipton, RB, Ferrari, MD, et al.Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project. [Review] [41 refs]. Curr Pain Headache Rep. 2004;8:43542.
28.Ferrari, MD.Current perspectives on effective migraine treatments: are small clinical differences important for patients? [Review] [9 refs]. Med Actual. 2003;39:3741.
29.Gawel, M, Aschoff, J, May, A, Charlesworth, BR, REALIZE Study T. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine-results from phase 1 of the REALIZE Study. Headache. 2005;45:716.
30.Tfelt-Hansen, P.Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials. Cephalalgia. 1993;13: 23844.
31.Dodick, D, Brandes, J, Elkind, A, Mathew, N, Rodichok, L.Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs. 2005;19:12536.
32.Dodick, DW, Sandrini, G, Williams, P.Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs. 2007;21:7382.
33.Dodick, D, Lipton, RB, Martin, V, et al.Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. [Review] [66 refs]. Headache. 2004; 44:41425.
34.Modgill, G, Jette, N, Wang, JL, Becker, WJ, Patten, SB.A population-based longitudinal community study of major depression and migraine. Headache. 2012;52:42232.
35.Jelinski, SE, Magnusson, JE, Becker, WJ, CHORd Study G. Factors associated with depression in patients referred to headache specialists. Neurology. 2007;68:48995.
36.Wenzel, RG, Tepper, S, Korab, WE, Freitag, F.Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA’s alert warranted? Ann Pharmacother. 2008;42:16926.
37.Evans, RW, Tepper, SJ, Shapiro, RE, Sun-edelstein, C, Tietjen, GE.The FdA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010;50: 108999.
38.Soldin, OP, Tonning, JM; Obstetric-Fetal Pharmacology Research Unit Network. Serotonin syndrome associated with triptan monotherapy. N Engl J Med. 2008 May 15;358(20):21856.
39.Headache Classification Subcommittee of the International Headache, Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24:9160.
40.Yates, R, Sorensen, J, Bergstrom, M, et al.Distribution of intranasal C-zolmitriptan assessed by positron emission tomography. Cephalalgia. 2005;25:11039.
41.Charlesworth, BR, Dowson, AJ, Purdy, A, Becker, WJ, Boes-Hansen, S, Farkkila, M.Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs. 2003;17:65367.
42.Ahrens, SP, Farmer, MV, Williams, DL, et al.Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia. 1999;19:52530.
43.Aurora, S, Kori, S, Barrodale, P, Nelsen, A, McDonald, S.Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache. 2007;47:14436.
44.Aurora, SK, Kori, SH, Barrodale, P, McDonald, SA, Haseley, D.Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache. 2006;46:5763.
45.Johannes, CB, Varas-Lorenzo, C, McQuay, LJ, Midkiff, KD, Fife, D.Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol drug Saf. 2010;19:8818.
46.Van Noord, C, Dieleman, JP, van Herpen, G, Verhamme, K, Sturkenboom, MC.Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Safety. 2010;33:100314.
47.Tokola, RA.The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. Cephalalgia. 1988;8:13947.
48.Tokola, RA, Neuvonen, PJ.Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984;17:6775.
49.Volans, GN.The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol. 1975;2: 5763.
50.MacGregor, EA, Wilkinson, M, Bancroft, K.Domperidone plus paracetamol in the treatment of migraine. Cephalalgia. 1993;13: 1247.
51.Schulman, EA, Dermott, KF.Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. [see comment]. Headache. 2003;43:72933.
52.Ferrari, MD, James, MH, Bates, D, et al.Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia. 1994;14:3308.
53.Brandes, JL, Kudrow, D, Stark, SR, et al.Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007; 297:144354.
54.Geraud, G, Keywood, C, Senard, JM.Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43:37688.
55.Winner, P, Ricalde, O, Le Force, B, Saper, J, Margul, B.A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. [see comment]. Arch Neurol. 1996;53:1804.
56.Teall, J, Tuchman, M, Cutler, N, et al.Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache. 1998;38:2817.
57.Tepper, SJ, Donnan, GA, Dowson, AJ, et al.A long-term study to maximise migraine relief with zolmitriptan. Curr Med Res Opin. 1999;15:25471.
58.Sheftell, F, Ryan, R, Pitman, V, Eletriptan Steering, C.Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache. 2003;43:20213.
59.Rapoport, AM, Ramadan, NM, Adelman, JU, et al.Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology. 1997;49:12108.
60.Bates, D, Ashford, E, Dawson, R, et al.Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology. 1994;44:158792.
61.Olesen, J, Diener, HC, Schoenen, J, Hettiarachchi, J.No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol. 2004;11:6717.
62.Dowson, A.Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura? Eur Neurol. 1996;36:2831.
63.Aurora, SK, Barrodale, PM, McDonald, SA, Jakubowski, M, Burstein, R.Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache. 2009;49:10014.
64.Artto, V, nissila, M, Wessman, M, Palotie, A, Farkkila, M, Kallela, M.Treatment of hemiplegic migraine with triptans. Eur J Neurol. 2007;14:10536.
65.Klapper, J, Mathew, N, Nett, R.Triptans in the treatment of basilar migraine and migraine with prolonged aura. Headache. 2001;41: 9814.
66.Brandes, JL, Kudrow, D, Stark, SR, et al.Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007; 297:144354.
67.Smith, TR, Sunshine, A, Stark, SR, Littlefield, DE, Spruill, SE, Alexander, WJ.Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45:98391.
68.Mathew, NT, Landy, S, Stark, S, et al.Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009;49:97182
69.Silberstein, SD, Mannix, LK, Goldstein, J, et al.Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology. 2008;71:11421.
70.Krymchantowski, AV.Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr. 2000;58:42830.
71.Jakubowski, M, Levy, D, Goor-Aryeh, I, Collins, B, Bajwa, Z, Burstein, R.Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache. 2005;45:85061.
72.Kelley, NE, Tepper, DE.Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications. Headache. 2012;52:46782.
73.Turkewitz, LJ, Casaly, JS, Dawson, GA, Wirth, O, Hurst, RJ, Gillette, PL.Self-administration of parenteral ketorolac tromethamine for head pain. Headache. 1992;32:4524.
74.Sandrini, G, Cerbo, R, Del Bene, E, et al.Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study. Int J Clin Pract. 2007;61:125669.
75.Di Monda, V, Nicolodi, M, Aloisio, A, et al.Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial. Headache. 2003;43:83544.
76.Kelley, NE, Tepper, DE.Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. Headache. 2012;52: 292306.
77.Jones, EB, Gonzalez, ER, Boggs, JG, Grillo, JA, Elswick, RK Jr., Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med. 1994;24:23741.
78.McEwen, JI, O’Connor, HM, Dinsdale, HB.Treatment of migraine with intramuscular chlorpromazine. Ann Emerg Med. 1987;16: 75863.
79.Rozen, TD.Migraine headache: immunosuppressant therapy. Curr Treat Options Neurol. 2002;4:395401.
80.Colman, I, Friedman, BW, Brown, MD, et al.Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008;336:135961.
81.Taheraghdam, AA, Amiri, H, Shojaan, H, Shamsvahdati, S, Houshyar, Y.Intravenous dexamethasone versus morphine in relieving of acute migraine headache. Pak J Biol Sci. 2011;14:6827.
82.Bigal, M, Sheftell, F, Tepper, S, Tepper, D, Ho, TW, Rapoport, A.A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache. 2008;48: 128693.
83.Boureau, F, Joubert, JM, Lasserre, V, Prum, B, Delecoeuillerie, G.Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia. 1994;14:15661.
84.Ho, TW, Rodgers, A, Bigal, ME.Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache. 2009; 49:395403.
85.Bigal, ME, Lipton, RB.Excessive acute migraine medication use and migraine progression. Neurology. 2008;71:18218.
86.De Felice, M, Porreca, F.Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache. Cephalalgia. 2009;29: 127784.
87.Madadi, P, Koren, G.Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics. 2008;9:126784.
88.Grond, S, Sablotzki, A.Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879923.
89.Tepper, SJ.Medication-overuse headache. CONTINUUM: Lifelong Learning in Neurology. 2012;18:80722.
90.Fisher, MA, Glass, S.Butorphanol (Stadol): a study in problems of current drug information and control. Neurology. 1997;48: 115660.
91.Bigal, ME, Lipton, RB.Acute treatment of migraine headache. Curr Treat Options neurol. 2003;5:42330.
92.Gerhardt, RT, Hermstad, E, Crawford, DM, Rayfield, J, Pfaff, J, Hunter, CJ.Postdischarge secobarbital after ED migraine treatment decreases pain and improves resolution. Am J emerg Med. 2011;29:8690.
93.Silberstein, SD, McCrory, DC.Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003;43:14466.
94.Lipton, RB.Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache. 1997;37:S3341.
95.Tfelt-Hansen, P, Saxena, PR, dahlof, C, et al.Ergotamine in the acute treatment of migraine: a review and european consensus. [Review] [84 refs]. Brain. 2000;123:918.
96.Baron, EP, Tepper, SJ.Revisiting the role of ergots in the treatment of migraine and headache. Headache. 2010;50:135361.
97.Bigal, ME, Tepper, SJ.Ergotamine and dihydroergotamine: a review. Curr Pain Headache Rep. 2003;7:5562.
98.MaassenVandenBrink, A, Reekers, M, Bax, WA, Ferrari, MD, Saxena, PR.Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998;98:2530.
99.Hoskin, KL, Kaube, H, Goadsby, PJ.Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain. 1996;119:24956.
100.Becker, WJ, Riess, CM, Hoag, J.Effectiveness of subcutaneous dihydroergotamine by home injection for migraine. Headache. 1996;36:1448.
101.Weisz, MA, El-Raheb, M, Blumenthal, HJ.Home administration of intramuscular DHE for the treatment of acute migraine headache. Headache. 1994;34:3713.
102.Klapper, JA, Stanton, J.Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches. Headache. 1992;32:213.
103.Rothrock, JF.Patient information regarding subcutaneous selfadministration of dihydroergotamine (DHE). Headache. 2007;47:740.
104.Raskin, NH.Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:9957.
105.Silberstein, SD, Schulman, EA, Hopkins, MM.Repetitive intravenous DHE in the treatment of refractory headache. Headache. 1990;30:3349.
106.Eadie, MJ.Ergot of rye-the first specific for migraine. J Clin Neurosci. 2004;11:47.
107.Schmidt, R, Fanchamps, A.Effect of caffeine on intestinal absorption of ergotamine in man. Eur J Clin Pharmacol. 1974;7:2136.
108.Evers, S, Gralow, I, Bauer, B, et al.Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. Clin Neuropharmacol. 1999;22:2016.
109.Dahlof, C.Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. [Review] [18 refs]. Cephalalgia. 1993;13:16671.
110.Diener, HC, Pfaffenrath, V, Pageler, L, Peil, H, Aicher, B.The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2005;25:77687.
111.Diener, HC, Peil, H, Aicher, B.The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: a post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2011;31:146676.
112.Laska, EM, Sunshine, A, Mueller, F, Elvers, WB, Siegel, C, Rubin, A.Caffeine as an analgesic adjuvant. JAMA. 1984;251:17118.
113.Ray, WA, Varas-Lorenzo, C, Chung, CP, et al.Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circulation. Circ Cardiovasc Qual Outcomes. 2009;2:15563.
114.Fosbol, EL, Folke, F, Jacobsen, S, et al.Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circulation. Circ Cardiovasc Qual Outcomes. 2010;3:395405.
115.Sauro, KM, Becker, WJ.Multidisciplinary treatment for headache in the Canadian healthcare setting. Can J Neurol Sci. 2008;35:4656.
116.MacGregor, EA, Victor, TW, Hu, X, et al.Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache. 2010;50:52838.
117.Diamond, ML, Cady, RK, Mao, L, et al.Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines. Headache. 2008;48:24858.
118.Mannix, LK, Loder, E, nett, R, et al.Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007;27:41421.
119.Tuchman, M, Hee, A, Emeribe, U, Silberstein, S.Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006;20:101926.
120.Pringsheim, T, Davenport, WJ, Dodick, D.Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology. 2008;70:155563.
121.Mannix, LK, Martin, VT, Cady, RK, et al.Combination treatment for menstrual migraine and dysmenorrhea using sumatriptannaproxen: two randomized controlled trials. Obstet Gynecol. 2009;114:10613.
122.Brandes, JL, Poole, A, Kallela, M, et al.Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia. 2009;29:113348.
123.Silberstein, SD, Elkind, AH, Schreiber, C, Keywood, C.A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:2619.
124.Tuchman, MM, Hee, A, Emeribe, U, Silberstein, S.Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs. 2008;22:87786.
125.Mannix, LK, Savani, N, Landy, S, et al.Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache. 2007;47:103749.
126.Sances, G, Martignoni, E, Fioroni, L, Blandini, F, Facchinetti, F, nappi, G.Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache. 1990;30:7059.
127.MacGregor, EA, Frith, A, Ellis, J, Aspinall, L, Hackshaw, A.Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology. 2006;67:215963.
128.Almen-Christensson, A, Hammar, M, Lindh-Astrand, L, Landtblom, AM, Brynhildsen, J.Prevention of menstrual migraine with perimenstrual transdermal 17-beta-estradiol: a randomized, placebo-controlled, double-blind crossover study. Fertil Steril. 2011;96:498500.e1.
129.Facchinetti, F, Sances, G, Borella, P, Genazzani, AR, Nappi, G.Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. 1991;31:298301.
130.Al-Waili, NS.Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo. Eur J Med Res. 2000;5:17682.
131.Teichmann, A, Apter, D, Emerich, J, et al.Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. Contraception. 2009;80:50411.
132.Reid, RL, Fortier, MP, Smith, L, Mirkin, S, Grubb, GS, Constantine, GD.Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada. Contraception. 2010;82:497502.
133.Coffee, AL, Sulak, PJ, Kuehl, TJ.Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception. 2007;75:4449.
134.Sulak, P, Willis, S, Kuehl, T, Coffee, A, Clark, J.Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache. 2007;47:2737.
135.Loder, E, Rizzoli, P, Golub, J.Hormonal management of migraine associated with menses and the menopause: a clinical review. Headache. 2007;47:32940.
136.Calhoun, A.Combined hormonal contraceptives: is it time to reassess their role in migraine? Headache. 2012;52:64860.
137.MacGregor, EA.Contraception and headache. Headache. 2013;53:24776.
138.Macintyre, PE, Schug, SA, Scott, DA, Visser, EJ, Walker, SM, APM: SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute pain management: scientific evidence. Melbourne: ANZA and FPM, 2010.
139.Nezvalova-Henriksen, K, Spigset, O, Nordeng, H.Effects of codeine on pregnancy outcome: Results from a large population-based cohort study. Eur J Clin Pharmacol. 2011;67:125361.
140.Nezvalova-Henriksen, K, Spigset, O, Nordeng, H.Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the norwegian Mother and Child Cohort Study. Headache. 2010;50:56375.
141.Duong, S, Bozzo, P, Nordeng, H, Einarson, A.Safety of triptans for migraine headaches during pregnancy and breastfeeding. Can Fam Physician. 2010;56:5379.
142.American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:77689.
143.Hendrickson, RG, McKeown, NJ.Is maternal opioid use hazardous to breast-fed infants? Clin Toxicol (Phila). 2012;50:114.
144.Rossi, P, Ambrosini, A, Buzzi, MG.Prodromes and predictors of migraine attack. Funct Neurol. 2005;20:18591.
145.Kelman, L.The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache. 2004;44:86572.
146.Schoonman, GG, Evers, DJ, Terwindt, GM, van Dijk, JG, Ferrari, MD.The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia. 2006;26:120913.
147.Quintela, E, Castillo, J, Munoz, P, Pascual, J.Premonitory and resolution symptoms in migraine: a prospective study in 100 unselected patients. Cephalalgia. 2006;26:105160.
148.Giffin, NJ, Ruggiero, L, Lipton, RB, et al.Premonitory symptoms in migraine: an electronic diary study. Neurology 2003;60:93540.
149.Waelkens, J.Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia. 1984;4:8590.
150.Luciani, R, Carter, D, Mannix, L, Hemphill, M, Diamond, M, Cady, R.Prevention of migraine during prodrome with naratriptan. Cephalalgia. 2000;20:1226.
151.Waelkens, J.Domperidone in the prevention of complete classical migraine. Br Med J (Clin Res ed). 1982;284:944.
152.Becker, WJ.The premonitory phase of migraine and migraine management. Cephalalgia. 2012 Feb 15;[epub ahead of print].
153.Jelinski, SE, Becker, WJ, Christie, SN, et al.Clinical features and pharmacological treatment of migraine patients referred to headache specialists in Canada. Cephalalgia. 2006;26:57888.
154.Derry, S, Moore, RA, McQuay, HJ.Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;008040.
155.Lipton, RB, Grosberg, B, Singer, RP, et al.Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia. 2010;30:133645.
156.Buchan, P, Keywood, C, Wade, A, Ward, C.Clinical pharmacokinetics of frovatriptan. Headache. 2002;42:S5462.
157.Johnston, MM, Rapoport, AM.Triptans for the management of migraine. Drugs. 2010;70:150518.
158.Derry, CJ, Derry, S, Moore, RA.Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane database Syst Rev. 2012;2:009665.
159.Derry, CJ, Derry, S, Moore, RA.Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2:009663.
160.Pascual, J, Falk, RM, Piessens, F, et al.Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia. 2000;20:58896.
161.Rapoport, A, Ryan, R, Goldstein, J, Keywood, C.Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache. 2002;42:S7483.
162.Derry, CJ, Derry, S, Moore, RA.Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2:008615.
163.Pryse-Phillips, WE, Dodick, DW, Edmeads, JG, et al.Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. [see comment][erratum appears in CMAJ 1997 Nov 15;157(10):1354]. [Review] [160 refs]. CMAJ. 1997;156:127387.

Related content

Powered by UNSILO

Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient

  • Irene Worthington (a1), Tamara Pringsheim (a2), Marek J. Gawel (a1) (a3) (a4), Jonathan Gladstone (a1) (a5), Paul Cooper (a6), Esma Dilli (a7), Michel Aube (a8), Elizabeth Leroux (a9), Werner J. Becker (a2) and on behalf of the Canadian Headache Society Acute Migraine Treatment Guideline Development Group...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.